Edition:
United States

Impax Laboratories Inc (IPXL.OQ)

IPXL.OQ on NASDAQ Stock Exchange Global Select Market

20.50USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$20.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
280,049
52-wk High
$25.70
52-wk Low
$7.80

Select another date:

Tue, Feb 13 2018

Valeant unit, Impax lose Solodyn antitrust class action appeal

A federal appeals court has declined to review an order certifying a class action by purchasers of the acne medication Solodyn alleging Medicis Pharmaceutical Corp sought to delay the launch of generic versions of the drug in violation of antitrust laws.

BRIEF-Maverick Capita Ltd Reports 9.9 pct Passive Stake In Impax Laboratories As Of Dec 31, 2017

* MAVERICK CAPITA, LTD REPORTS 9.9 PERCENT PASSIVE STAKE IN IMPAX LABORATORIES AS OF DEC 31, 2017 - SEC FILING‍​ Source text - (http://bit.ly/2srwpqz) Further company coverage:

BRIEF-Bora Pharmaceuticals buys pharma firm owned by Impax Laboratories for $18.5 mln

* Says it completed acquisition of 100 percent stake in a pharmaceutical company owned by Impax Laboratories,Inc for $18.5 million

Valeant unit, Impax lose bid to escape Solodyn antitrust class action

A federal judge has cleared the way for a trial in a class action by purchasers of the acne medication Solodyn who claim Medicis Pharmaceutical Corp violated antitrust law by striking deals to delay the launch of generic versions of the drug.

BRIEF-Impax Receives Tentative fda Approval Of Generic Coreg CR (Carvedilol Phosphate) Extended-Release Capsules

* IMPAX RECEIVES TENTATIVE FDA APPROVAL OF GENERIC COREG CR® (CARVEDILOL PHOSPHATE) EXTENDED-RELEASE CAPSULES

BRIEF-Impax Laboratories says co entered into amendment no. 1 to business combination agreement with Atlas Holdings ​

* Impax Laboratories Inc - ‍on Nov 21, co entered into amendment no. 1 to business combination agreement, dated October 17, 2017 with Atlas Holdings ​

BRIEF-Impax Laboratories says board of co amended and restated bylaws of co

* Impax Laboratories says ‍on and effective Nov 10, 2017, board of co amended and restated bylaws of company - SEC filing

BRIEF-Impax Q3 adjusted earnings per share $0.23

* Q3 earnings per share view $0.20 -- Thomson Reuters I/B/E/S

BRIEF-Impax gets FDA approval for generic Renvela tablets

* Impax announces FDA approval and launch of generic Renvela (sevelamer carbonate) tablets, 800 mg

UPDATE 3-Amneal, Impax combine to tackle generic drug pricing pressure

* Impax was expected to keep >25 pct stake - analyst (Adds analysts' comments, background on retail pharmacies; updates shares)

Select another date: